https://www.nasdaq.com/press-release/akari-therapeutics-to-present-at-h.c.-wainwright-bioconnect-virtual-conference-2022
https://www.nasdaq.com/press-release/akari-therapeutics-plc-announces-%246.0-million-registered-direct-offering-2021-12-30
https://www.nasdaq.com/press-release/akari-therapeutics-reports-third-quarter-2021-financial-results-and-highlights-recent
https://www.nasdaq.com/press-release/akari-therapeutics-presents-new-data-revealing-potential-mechanism-of-action-driving
https://www.nasdaq.com/press-release/akari-therapeutics-announces-presentation-at-annual-complement-based-drug-development
https://www.nasdaq.com/press-release/akari-therapeutics-announces-new-data-with-nomacopan-from-its-surface-of-the-eye
https://www.nasdaq.com/press-release/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/akari-therapeutics-reports-second-quarter-2021-financial-results-and-highlights
https://www.nasdaq.com/press-release/akari-therapeutics-to-present-its-phase-iii-plans-for-nomacopan-in-patients-with
https://www.nasdaq.com/press-release/akari-therapeutics-to-present-at-the-h.c.-wainwright-global-investment-conference
https://www.nasdaq.com/press-release/akari-therapeutics-announces-private-placement-2021-07-07
https://www.nasdaq.com/press-release/akari-therapeutics-reports-q1-2021-financial-results-and-highlights-recent-clinical
https://www.nasdaq.com/press-release/akari-therapeutics-receives-fda-fast-track-designation-for-nomacopan-for-the
https://www.nasdaq.com/press-release/akari-therapeutics-announces-poster-presentation-of-phase-ii-bullous-pemphigoid
https://www.nasdaq.com/press-release/akari-therapeutics-reports-full-year-2020-financial-results-and-highlights-recent
https://www.nasdaq.com/press-release/akari-therapeutics-announces-initiation-of-pivotal-phase-iii-trial-of-nomacopan-in-0
https://www.nasdaq.com/press-release/akari-therapeutics-announces-a-cooperative-research-and-development-agreement-crada
https://www.nasdaq.com/press-release/akari-therapeutics-presents-new-preclinical-data-highlighting-potential-of-long
https://www.nasdaq.com/press-release/akari-therapeutics-adds-histamine-inhibitor-votucalis-to-pipeline-to-treat
https://www.nasdaq.com/press-release/akari-therapeutics-to-participate-in-two-january-virtual-investor-conferences-2021-01
https://www.nasdaq.com/press-release/akari-therapeutics-reports-third-quarter-2020-financial-results-and-highlights-recent
https://www.nasdaq.com/press-release/akari-therapeutics-announces-new-clinical-data-that-show-long-term-self-administered
https://www.nasdaq.com/press-release/akari-therapeutics-announces-publication-in-american-journal-of-pathology
https://www.nasdaq.com/press-release/akari-therapeutics-to-present-phase-ii-data-from-bullous-pemphigoid-trial-at-european
https://www.nasdaq.com/press-release/akari-therapeutics-announces-further-clinical-trial-progress-using-nomacopan-to-treat
https://www.nasdaq.com/press-release/akari-therapeutics-announces-successful-scientific-advice-meeting-with-the-european
https://www.nasdaq.com/press-release/akari-therapeutics-to-present-its-phase-iii-plans-at-the-international-pemphigus
https://www.nasdaq.com/press-release/akari-therapeutics-to-participate-in-two-september-virtual-investor-conferences-2020
https://www.nasdaq.com/press-release/akari-therapeutics-reports-second-quarter-2020-financial-results-and-highlights
https://www.nasdaq.com/press-release/akari-therapeutics-announces-international-clinical-development-program-of-nomacopan
https://www.nasdaq.com/press-release/akari-therapeutics-announces-successful-end-of-phase-ii-meeting-with-fda-to-initiate
https://www.nasdaq.com/press-release/akari-therapeutics-enters-into-a-securities-purchase-agreement-for-up-to-%2430-million
https://www.nasdaq.com/press-release/akari-therapeutics-announces-appointment-of-chief-financial-officer-2020-07-01
https://www.nasdaq.com/press-release/akari-therapeutics-reports-first-quarter-2020-financial-results-and-highlights-recent
https://www.nasdaq.com/press-release/akari-therapeutics-receives-positive-ema-opinion-on-orphan-designation-for-nomacopan
https://www.nasdaq.com/press-release/akari-therapeutics-to-participate-in-strh-life-sciences-virtual-meeting-series-2020
https://www.nasdaq.com/press-release/akari-therapeutics-announces-positive-topline-results-from-fully-recruited-phase-ii
https://www.nasdaq.com/press-release/akari-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/akari-therapeutics-plc-announces-closing-of-%249.5-million-private-placement-2020-03-04
https://www.nasdaq.com/press-release/akari-therapeutics-plc-announces-private-placement-2020-02-20
https://www.nasdaq.com/press-release/akari-therapeutics-announces-preclinical-ophthalmic-data-showing-nomacopan-reduces
https://www.nasdaq.com/press-release/akari-therapeutics-announces-positive-interim-data-from-phase-iii-paroxysmal
https://www.nasdaq.com/press-release/akari-therapeutics-announces-initiation-of-pivotal-phase-iii-trial-of-nomacopan-in
https://www.nasdaq.com/press-release/akari-therapeutics-announces-pivotal-phase-iii-trial-design-of-nomacopan-in-pediatric
https://www.nasdaq.com/press-release/akari-therapeutics-reports-third-quarter-2019-financial-results-and-highlights-recent
https://www.nasdaq.com/press-release/akari-therapeutics-announces-new-data-from-atopic-keratoconjunctivitis-akc-patients
https://www.nasdaq.com/press-release/akari-therapeutics-announces-positive-phase-ii-clinical-data-in-orphan-blistering
https://www.nasdaq.com/press-release/akari-therapeutics-to-participate-in-ladenburg-thalmann-healthcare-conference-2019-09
